Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Shares Acquired by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.

Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its stake in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNAFree Report) by 9.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 225,037 shares of the company’s stock after acquiring an additional 19,858 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Ginkgo Bioworks were worth $407,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in DNA. Yousif Capital Management LLC purchased a new position in shares of Ginkgo Bioworks during the second quarter worth about $25,000. Creative Planning purchased a new stake in Ginkgo Bioworks in the 4th quarter valued at approximately $25,000. Silverlake Wealth Management LLC purchased a new stake in Ginkgo Bioworks in the 4th quarter valued at approximately $25,000. Private Advisor Group LLC purchased a new stake in Ginkgo Bioworks in the 1st quarter valued at approximately $26,000. Finally, Aspen Grove Capital LLC purchased a new stake in Ginkgo Bioworks in the 1st quarter valued at approximately $27,000. Hedge funds and other institutional investors own 56.84% of the company’s stock.

Ginkgo Bioworks Price Performance

Shares of NYSE:DNA opened at $1.29 on Wednesday. The business’s 50 day simple moving average is $1.44 and its 200-day simple moving average is $1.65. Ginkgo Bioworks Holdings, Inc. has a 12 month low of $1.12 and a 12 month high of $2.55.

Ginkgo Bioworks (NYSE:DNAGet Free Report) last issued its quarterly earnings data on Wednesday, November 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.09). Ginkgo Bioworks had a negative return on equity of 36.36% and a negative net margin of 272.30%. The firm had revenue of $55.43 million during the quarter, compared to the consensus estimate of $46.47 million. Equities research analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.42 EPS for the current fiscal year.

Analysts Set New Price Targets

DNA has been the topic of a number of analyst reports. BTIG Research lowered Ginkgo Bioworks from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. The Goldman Sachs Group lowered their price objective on Ginkgo Bioworks from $1.25 to $1.10 and set a “sell” rating on the stock in a report on Monday, January 22nd. Finally, Raymond James lowered Ginkgo Bioworks from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $3.50 to $2.50 in a research note on Tuesday, November 14th.

View Our Latest Stock Report on DNA

Insider Buying and Selling

In related news, insider Jason R. Kelly sold 100,000 shares of Ginkgo Bioworks stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $1.54, for a total transaction of $154,000.00. Following the completion of the transaction, the insider now directly owns 5,194,680 shares in the company, valued at approximately $7,999,807.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Jason R. Kelly sold 100,000 shares of Ginkgo Bioworks stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $1.54, for a total transaction of $154,000.00. Following the completion of the transaction, the insider now directly owns 5,194,680 shares in the company, valued at approximately $7,999,807.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Barry Canton sold 37,650 shares of the business’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $1.40, for a total value of $52,710.00. Following the completion of the transaction, the insider now owns 12,525,154 shares of the company’s stock, valued at $17,535,215.60. The disclosure for this sale can be found here. Insiders sold 1,043,720 shares of company stock worth $1,524,693 in the last ninety days. Insiders own 15.05% of the company’s stock.

About Ginkgo Bioworks

(Free Report)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

See Also

Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNAFree Report).

Institutional Ownership by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.